If You Invested in Cv Sciences (CVSI)

CV Sciences, Inc. (OTCQB: CVSI) is described as a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed natural ingredients and products. Although classified under "All Other Miscellaneous Chemical Product and Preparation Manufacturing" in the Manufacturing sector, the company consistently presents itself as a consumer wellness, nutraceutical, and plant-based foods business.

According to multiple company press releases, CV Sciences focuses on nutraceuticals and plant-based foods that incorporate hemp extracts and other natural ingredients. Its products are sold through a range of sales channels from B2B to B2C, reflecting a mix of wholesale and direct-to-consumer distribution. The company’s common stock trades on the OTCQB market under the ticker symbol CVSI.

Core Brands and Product Focus

CV Sciences highlights several key brands:

• +PlusCBD™: A hemp-extract supplement brand. Company disclosures state that +PlusCBD™ branded products are sold at select retail locations throughout the U.S. and are the top-selling hemp-extract brand in the natural products market, according to SPINS, a provider of syndicated data and insights for the natural, organic and specialty products industry. The company emphasizes that +PlusCBD™ product benefits in healthy people are supported by human clinical research data, including three published clinical case studies available on PubMed.gov. +PlusCBD™ was also the first hemp extract supplement brand at the company to invest in scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status.
• +PlusHLTH™: A cannabinoid-free supplement brand. CV Sciences states that +PlusHLTH™ offers targeted formulations to optimize health, improve performance, and increase vitality. These products are positioned alongside the company’s cannabinoid supplements and topicals, providing diversification within its wellness portfolio.
• Cultured Foods™: A plant-based food brand. Company materials describe Cultured Foods™ as providing a variety of 100% plant-based food products distributed primarily in the European Union and other select markets. The brand is aimed at individuals seeking vegan, gluten-free, or flexitarian options for a wholesome and satisfying culinary experience.
• Lunar Fox: A plant-based company and product line launched by CV Sciences. The initial Lunar Fox offering includes seven products that provide plant-based alternatives for traditional, animal-based proteins, including vegan cheese, egg, and meat products. Company disclosures state that all Lunar Fox products are vegan, sustainable and nutritious food alternatives addressing consumer needs in the growing vegan category. Lunar Fox products are described as being available at select retailers in the U.S. market and online.
• Elevated Softgels: CV Sciences owns Elevated Softgels, which it describes as a leading manufacturer of encapsulated softgels and tinctures for the supplement and nutrition industry. This business supports in-sourcing of production for many of the company’s products and is referenced in connection with efforts to improve gross margin over time.

Hemp Extracts, CBD and Science-Backed Positioning

Across its communications, CV Sciences emphasizes that its hemp extracts and other natural ingredients and products are supported by evidence-based science. The company notes that +PlusCBD™ products are backed by human clinical research data and that it has invested in the scientific evidence needed for self-affirmed GRAS status. This science-forward positioning is central to how CV Sciences presents its role in the hemp-derived wellness category.

The company’s news releases also discuss hemp-derived cannabinoid products, primarily containing CBD, as having potential to improve symptoms associated with common ailments such as pain, sleep, and anxiety. CV Sciences publicly applauds regulatory and policy developments that support science-based, regulated access to full-spectrum CBD products, and it highlights its long-standing commitment to evidence-based science.

Plant-Based Foods and Global Reach

In addition to hemp-derived supplements, CV Sciences is building a broader plant-based foods platform. Through Cultured Foods™ and Lunar Fox, the company offers plant-based alternatives to traditional animal-based proteins and other foods. Company statements indicate that Cultured Foods™ products are distributed primarily in the EU and select international markets, while Lunar Fox targets the U.S. market with vegan cheese, egg, and meat alternatives.

These brands are positioned toward consumers who identify as vegan, gluten-free, or flexitarian, and who seek plant-based options. CV Sciences describes the launch of Lunar Fox as a key milestone in its transition to a global health and wellness company.

Sales Channels and Market Position

CV Sciences reports that its hemp extracts and other products are sold through B2B and B2C channels. B2B sales are influenced by state-level regulations for CBD, while B2C sales include direct-to-consumer activity and retail distribution. The company notes that its +PlusCBD™ branded products are sold at select retail locations throughout the United States.

According to repeated company disclosures citing SPINS data, +PlusCBD™ is the top-selling hemp-extract brand in the natural products market retail channel. CV Sciences also reports that a significant portion of its net revenue in recent periods has come from new products launched since January 1, 2023, reflecting an ongoing emphasis on product innovation within its wellness and plant-based portfolios.

Regulatory and Policy Engagement

CV Sciences’ news releases show active engagement with the evolving regulatory environment for hemp and CBD. The company has:

• Publicly applauded a U.S. presidential executive order aimed at improving cannabidiol research to better inform patients and doctors, particularly in relation to full-spectrum CBD products and real-world evidence models.
• Highlighted a planned Medicare and Medicaid Pilot Program for CBD products, with the stated goal of allowing senior patients to obtain CBD products with reimbursement through Medicare and Medicaid. CV Sciences describes itself as strongly positioned to participate in such a program, citing its decade-long commitment to evidence-based science and GRAS status for its hemp extract supplements.
• Praised the veto of Texas Senate Bill 3, which the company states would have effectively banned many consumable hemp products in Texas. CV Sciences frames this veto as important for maintaining consumer access to federally legal hemp-derived wellness products and for supporting the hemp industry.

These activities underscore the company’s focus on regulatory advocacy and policy engagement around hemp-derived products and CBD.

Financial Reporting and Capital Structure

CV Sciences regularly reports its financial results through press releases and SEC filings, including quarterly and annual financial statements. The company discusses metrics such as product sales, gross margin, operating income or loss, adjusted EBITDA, and cash balances. It explains that it uses non-GAAP measures like Adjusted EBITDA internally to evaluate performance, adjusting for items such as stock-based compensation and other non-cash expenses.

SEC Form 8-K filings describe material definitive agreements related to secured promissory notes and note purchase agreements with institutional investors. These filings detail original issuance discounts, maturity dates, repayment schedules, security interests in company and subsidiary assets, and events of default. The company notes that certain notes are secured by all of its assets and the assets of its subsidiaries, and that it has entered into security and intellectual property security agreements in connection with these financings.

Operations and Locations

Company disclosures state that CV Sciences, Inc. has primary offices and facilities in San Diego, California, Grand Junction, Colorado, and Warsaw, Poland. These locations support its operations in hemp-derived wellness products, plant-based foods, and softgel and tincture manufacturing.

Business Evolution and Product Innovation

Across its recent communications, CV Sciences emphasizes:

• Ongoing product innovation, including the launch of +PlusHLTH™ supplements, +PlusCBD™ Extra Support Sleep and Calm Gummies, +PlusCBD™ Reserve gummies, +PlusCBD™ pet products, and the Ignite men's performance formula.
• Portfolio diversification beyond CBD, through cannabinoid-free supplements and plant-based food brands such as Cultured Foods™ and Lunar Fox.
• An intention to build an efficient and cost-effective consumer products platform, including through acquisitions such as Elevated Softgels and through evaluating inbound and outbound merger, sale, acquisition or other corporate opportunities.

According to the company, these steps are intended to support a more balanced product portfolio across hemp-derived wellness, supplements, and plant-based foods.

FAQs about CV Sciences, Inc. (CVSI)